AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Takeda Pharmaceutical Company Limited
Video analysis: TAK
All videosNo video analysis for this stock yet. Request one from our team.
News: TAK
Best Value Stocks to Buy for September 14th
SIG, TAK and TX made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 14th, 2026.
Best Income Stocks to Buy for September 14th
TX, HPQ and TAK made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 14th, 2026.
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda's Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque ps.
Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026
MALMO, Sweden & WILMINGTON, Del.--(BUSINESS WIRE)--Trialbee, the global patient recruitment leader reimagining clinical trials with AI, will present alongside Takeda at DPHARM 2026 taking place September 15–16 in Boston. During the event, Trialbee will unveil AI patient screening in its Honey Platform™, the next release on the Applied AI Recruitment roadmap it published earlier this year. Trialbee will also take an active role participating in a panel on AI technology for clinical sites in the.
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1. "People living with narcolepsy type 1 face persistent symptoms across the day and night, which can impact many aspects of daily l.
Critical Survey: ABVC BioPharma (NASDAQ:ABVC) vs. Takeda Pharmaceutical (NYSE:TAK)
ABVC BioPharma (NASDAQ: ABVC - Get Free Report) and Takeda Pharmaceutical (NYSE: TAK - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership. Risk and Volatility ABVC BioPharma has a beta
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities
SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 active programs in multiple global markets. The collaboration brings together Weave's AI capabilities and Takeda's regulatory expertise to support innovation in regulatory workflows. “Regulatory communications are the most knowledge-intensive workflows in all of drug development, and for too long that kn.
Similar companies
-
Haleon plc
HLN
·
New York Stock Exchange
Compare
-
Agilent Technologies, Inc.
A
·
New York Stock Exchange
Compare
-
Cardinal Health, Inc.
CAH
·
New York Stock Exchange
Compare
-
Insmed Incorporated
INSM
·
NASDAQ
Compare
-
IQVIA Holdings Inc.
IQV
·
New York Stock Exchange
Compare
-
Alcon Inc.
ALC
·
New York Stock Exchange
Compare